Hypertension
Conditions
Keywords
Essential Hypertension, Cardiovascular Disease, High Blood Pressure, Drug Therapy
Brief summary
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to placebo, valsartan and olmesartan in participants with essential hypertension.
Detailed description
Hypertension affects approximately 50 million individuals in the United States. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. Despite the availability of antihypertensive treatments, hypertension remains inadequately controlled: only about one-third of patients successfully maintain control. A major component of blood pressure regulation is the renin-angiotensin-aldosterone system. This is a system of hormone-mediated feedback interactions that result in the relaxation or constriction of blood vessels in response to various stimuli. Angiotensin II, a polypeptide hormone, is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme as part of the renin-angiotensin-aldosterone system. Angiotensin II is the principal pressor agent of the renin-angiotensin-aldosterone system and has multiple effects on the cardiovascular system and on electrolyte homeostasis. TAK-491 (azilsartan medoxomil) is an angiotensin II type 1 receptor antagonist currently being tested as a treatment for essential hypertension. Study participation is anticipated to be about 10 weeks. Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, physical examinations, electrocardiograms and ambulatory blood pressure monitoring. Outside of the study center, participants will be required wear an ambulatory blood pressure monitoring device at 24 hour intervals.
Interventions
Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks. Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.
DRUGValsartan
Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks. Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.
DRUGOlmesartan
Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks. Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.
DRUGPlacebo
Matching placebo, orally, once daily for up to six weeks.
Sponsors
Takeda
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Essential hypertension (sitting systolic blood pressure between 150 and 180 mm Hg, inclusive, at Day -1 and 24-hour mean systolic blood pressure between 130 and 170 mm Hg, inclusive, at Day 1). 2. Capable of understanding and complying with protocol requirements. 3. Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study 4. Clinical laboratory evaluations within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator. 5. Willing to discontinue current antihypertensive medications at Screening Day 21 visit. If the participant is on amlodipine prior to Screening, the participant is willing to discontinue this medication at Screening Day -28.
Exclusion criteria
1. Sitting diastolic blood pressure greater than 114 mm Hg at Day -1 (day prior to Randomization). 2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality. 3. Taking or expected to take an excluded medication as described in the Excluded Medications. 4. Hypersensitive to angiotensin II receptor blockers. 5. History of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack. 6. Clinically significant cardiac conduction defects. 7. Hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease. 8. Secondary hypertension of any etiology. 9. Noncompliant (less than 70% or greater than 130%) with study medication during run-in period. 10. Moderate to severe renal dysfunction or disease. 11. Known or suspected unilateral or bilateral renal artery stenosis. 12. History of drug or alcohol abuse within the past 2 years. 13. Previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. (This criterion does not apply to those participants with basal cell or stage I squamous cell carcinoma of the skin). 14. Type 1 or poorly-controlled type 2 diabetes mellitus (glycosylate hemoglobin greater than 8.0%) at Screening. 15. Hyperkalemia as defined by the central laboratory normal reference range at Screening. 16. Alanine aminotransferase level of greater than 2.5 times the upper limit of normal, active liver disease, or jaundice at Screening. 17. Upper arm circumference less than 24 cm or greater than 42 cm. 18. Works night (3rd) shift (defined as 11 PM \[2300\] to 7 AM \[0700\]). 19. Unwilling or unable to comply with the protocol or scheduled appointments. 20. Currently is participating in another investigational study or has participated in an investigational study within 30 days prior to Randomization. 21. Any other serious disease or condition at Screening or Randomization that would compromise participant's safety, might affect life expectancy, or make it difficult to successfully manage and follow the subject according to the protocol. 22. Has been randomized in a previous azilsartan medoxomil study. 23. Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. |
| Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure | Baseline and Week 6. | The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline. |
| Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. |
| Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. |
| Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. |
| Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. |
| Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure. | Baseline and Week 6. | The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline. |
| Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. |
| Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing. |
| Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing. |
| Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg | Baseline and Week 6. | Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements. |
| Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg | Baseline and Week 6. | Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements. |
| Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response | Baseline and Week 6. | Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements. |
| Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | Baseline and Week 6. | The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. |
Countries
Argentina, Brazil, Mexico, Peru, Puerto Rico, United States
Participant flow
Recruitment details
Participants enrolled at 141 investigative sites in Guatemala, Mexico, Peru, Puerto Rico and the United States from 02 April 2008 to 19 August 2009.
Pre-assignment details
Participants with essential hypertension were enrolled in one of five, once-daily (QD) treatment groups.
Participants by arm
| Arm | Count |
|---|---|
| Azilsartan Medoxomil 40 mg QD Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks. | 280 |
| Azilsartan Medoxomil 80 mg QD Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks. | 285 |
| Valsartan 320 mg QD Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks. | 282 |
| Olmesartan 40 mg QD Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks. | 290 |
| Placebo QD Matching placebo, orally, once daily for up to six weeks. | 154 |
| Total | 1,291 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Overall Study | Administrative Decision | 1 | 0 | 0 | 0 | 0 |
| Overall Study | Administrative Error | 2 | 0 | 2 | 0 | 0 |
| Overall Study | Adverse Event | 7 | 9 | 8 | 6 | 4 |
| Overall Study | Lack of Efficacy | 3 | 1 | 5 | 2 | 4 |
| Overall Study | Lost to Follow-up | 1 | 6 | 2 | 4 | 3 |
| Overall Study | Missing | 0 | 1 | 1 | 0 | 0 |
| Overall Study | Participant Non-compliance | 0 | 0 | 1 | 2 | 0 |
| Overall Study | Participant Unavailability | 2 | 0 | 2 | 1 | 0 |
| Overall Study | Protocol Violation | 3 | 2 | 2 | 0 | 1 |
| Overall Study | Withdrawal by Subject | 4 | 11 | 5 | 7 | 1 |
Baseline characteristics
| Characteristic | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Valsartan 320 mg QD | Olmesartan 40 mg QD | Placebo QD | Total |
|---|---|---|---|---|---|---|
| Age Categorical <45 years | 41 participants | 38 participants | 56 participants | 39 participants | 20 participants | 194 participants |
| Age Categorical ≥65 years | 69 participants | 63 participants | 48 participants | 66 participants | 36 participants | 282 participants |
| Age Categorical Between 45 and 64 years | 170 participants | 184 participants | 178 participants | 185 participants | 98 participants | 815 participants |
| Sex: Female, Male Female | 133 Participants | 134 Participants | 130 Participants | 131 Participants | 64 Participants | 592 Participants |
| Sex: Female, Male Male | 147 Participants | 151 Participants | 152 Participants | 159 Participants | 90 Participants | 699 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 18 / 280 | 12 / 284 | 21 / 277 | 23 / 290 | 14 / 155 |
| serious Total, serious adverse events | 2 / 280 | 3 / 284 | 3 / 277 | 4 / 290 | 2 / 155 |
Outcome results
Primary
Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 6.
Population: Full Analysis Set.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Azilsartan Medoxomil 40 mg QD | Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -13.42 mmHg | Standard Error 0.69 |
| Azilsartan Medoxomil 80 mg QD | Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -14.53 mmHg | Standard Error 0.702 |
| Valsartan 320 mg QD | Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -10.22 mmHg | Standard Error 0.696 |
| Olmesartan 40 mg QD | Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -11.99 mmHg | Standard Error 0.666 |
| Placebo QD | Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -0.25 mmHg | Standard Error 0.917 |
p-value: <0.00195% CI: [-16.54, -12.01]ANCOVA
p-value: <0.00195% CI: [-15.41, -10.91]ANCOVA
p-value: 0.00995% CI: [-4.44, -0.64]ANCOVA
p-value: <0.00195% CI: [-6.25, -2.37]ANCOVA
p-value: 0.13695% CI: [-3.31, 0.45]ANCOVA
p-value: 0.00195% CI: [-5.12, -1.27]ANCOVA
Secondary
Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 6.
Population: Full Analysis Set.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Azilsartan Medoxomil 40 mg QD | Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -8.96 mmHg | Standard Error 0.51 |
| Azilsartan Medoxomil 80 mg QD | Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -9.80 mmHg | Standard Error 0.518 |
| Valsartan 320 mg QD | Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -7.23 mmHg | Standard Error 0.514 |
| Olmesartan 40 mg QD | Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -7.82 mmHg | Standard Error 0.492 |
| Placebo QD | Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | 0.01 mmHg | Standard Error 0.677 |
p-value: <0.00195% CI: [-11.48, -8.13]ANCOVA
p-value: <0.00195% CI: [-10.63, -7.3]ANCOVA
p-value: 0.00695% CI: [-3.39, -0.58]ANCOVA
p-value: <0.00195% CI: [-4, -1.14]ANCOVA
p-value: 0.10795% CI: [-2.53, 0.25]ANCOVA
p-value: 0.01795% CI: [-3.15, -0.3]ANCOVA
Secondary
Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 6.
Population: Full Analysis Set.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Azilsartan Medoxomil 40 mg QD | Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -13.73 mmHg | Standard Error 0.724 |
| Azilsartan Medoxomil 80 mg QD | Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -15.02 mmHg | Standard Error 0.736 |
| Valsartan 320 mg QD | Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -10.26 mmHg | Standard Error 0.73 |
| Olmesartan 40 mg QD | Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -12.16 mmHg | Standard Error 0.699 |
| Placebo QD | Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -0.11 mmHg | Standard Error 0.963 |
p-value: <0.00195% CI: [-17.3, -12.54]ANCOVA
p-value: <0.00195% CI: [-15.99, -11.27]ANCOVA
p-value: 0.00595% CI: [-4.85, -0.87]ANCOVA
p-value: <0.00195% CI: [-6.8, -2.73]ANCOVA
p-value: 0.11995% CI: [-3.55, 0.4]ANCOVA
p-value: <0.00195% CI: [-5.49, -1.45]ANCOVA
Secondary
Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.
Time frame: Baseline and Week 6.
Population: Full analysis set with last observation carried forward.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Azilsartan Medoxomil 40 mg QD | Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure | -6.97 mmHg | Standard Error 0.552 |
| Azilsartan Medoxomil 80 mg QD | Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure | -8.27 mmHg | Standard Error 0.551 |
| Valsartan 320 mg QD | Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure | -5.11 mmHg | Standard Error 0.55 |
| Olmesartan 40 mg QD | Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure | -6.10 mmHg | Standard Error 0.538 |
| Placebo QD | Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure | -0.76 mmHg | Standard Error 0.744 |
p-value: <0.00195% CI: [-9.33, -5.69]ANCOVA
p-value: <0.00195% CI: [-8.03, -4.39]ANCOVA
p-value: 0.00595% CI: [-3.69, -0.67]ANCOVA
p-value: <0.00195% CI: [-4.69, -1.64]ANCOVA
p-value: 0.25795% CI: [-2.39, 0.64]ANCOVA
p-value: 0.01795% CI: [-3.39, -0.33]ANCOVA
Secondary
Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.
The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.
Time frame: Baseline and Week 6.
Population: Full analysis set with last observation carried forward.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Azilsartan Medoxomil 40 mg QD | Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure. | -16.38 mmHg | Standard Error 0.959 |
| Azilsartan Medoxomil 80 mg QD | Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure. | -16.74 mmHg | Standard Error 0.957 |
| Valsartan 320 mg QD | Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure. | -11.31 mmHg | Standard Error 0.955 |
| Olmesartan 40 mg QD | Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure. | -13.20 mmHg | Standard Error 0.935 |
| Placebo QD | Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure. | -1.83 mmHg | Standard Error 1.293 |
p-value: <0.00195% CI: [-18.07, -11.76]ANCOVA
p-value: <0.00195% CI: [-17.71, -11.4]ANCOVA
p-value: 0.00895% CI: [-6.17, -0.92]ANCOVA
p-value: <0.00195% CI: [-8.09, -2.78]ANCOVA
p-value: 0.01895% CI: [-5.81, -0.55]ANCOVA
p-value: <0.00195% CI: [-7.73, -2.42]ANCOVA
Secondary
Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 6.
Population: Full Analysis Set.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Azilsartan Medoxomil 40 mg QD | Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -9.16 mmHg | Standard Error 0.542 |
| Azilsartan Medoxomil 80 mg QD | Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -10.13 mmHg | Standard Error 0.551 |
| Valsartan 320 mg QD | Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -7.42 mmHg | Standard Error 0.547 |
| Olmesartan 40 mg QD | Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -7.82 mmHg | Standard Error 0.524 |
| Placebo QD | Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | 0.01 mmHg | Standard Error 0.721 |
p-value: <0.00195% CI: [-11.92, -8.36]ANCOVA
p-value: <0.00195% CI: [-10.94, -7.4]ANCOVA
p-value: 0.00295% CI: [-3.81, -0.82]ANCOVA
p-value: <0.00195% CI: [-4.24, -1.19]ANCOVA
p-value: 0.07695% CI: [-2.82, 0.14]ANCOVA
p-value: 0.02495% CI: [-3.25, -0.22]ANCOVA
Secondary
Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 6.
Population: Full Analysis Set.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Azilsartan Medoxomil 40 mg QD | Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -14.03 mmHg | Standard Error 0.764 |
| Azilsartan Medoxomil 80 mg QD | Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -15.55 mmHg | Standard Error 0.777 |
| Valsartan 320 mg QD | Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -10.44 mmHg | Standard Error 0.77 |
| Olmesartan 40 mg QD | Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -12.23 mmHg | Standard Error 0.738 |
| Placebo QD | Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -0.10 mmHg | Standard Error 1.016 |
p-value: <0.00195% CI: [-17.96, -12.94]ANCOVA
p-value: <0.00195% CI: [-16.42, -11.43]ANCOVA
p-value: 0.00295% CI: [-5.42, -1.22]ANCOVA
p-value: <0.00195% CI: [-7.26, -2.97]ANCOVA
p-value: 0.09195% CI: [-3.88, 0.29]ANCOVA
p-value: <0.00195% CI: [-5.72, -1.46]ANCOVA
Secondary
Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 6.
Population: Full Analysis Set.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Azilsartan Medoxomil 40 mg QD | Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -8.65 mmHg | Standard Error 0.472 |
| Azilsartan Medoxomil 80 mg QD | Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -9.43 mmHg | Standard Error 0.48 |
| Valsartan 320 mg QD | Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -7.09 mmHg | Standard Error 0.476 |
| Olmesartan 40 mg QD | Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -7.74 mmHg | Standard Error 0.456 |
| Placebo QD | Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -0.07 mmHg | Standard Error 0.627 |
p-value: <0.00195% CI: [-10.91, -7.81]ANCOVA
p-value: <0.00195% CI: [-10.12, -7.04]ANCOVA
p-value: 0.01195% CI: [-2.99, -0.4]ANCOVA
p-value: <0.00195% CI: [-3.67, -1.02]ANCOVA
p-value: 0.16695% CI: [-2.19, 0.38]ANCOVA
p-value: 0.0295% CI: [-2.88, -0.24]ANCOVA
Secondary
Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 6.
Population: Full Analysis Set.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Azilsartan Medoxomil 40 mg QD | Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -7.65 mmHg | Standard Error 0.54 |
| Azilsartan Medoxomil 80 mg QD | Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -8.54 mmHg | Standard Error 0.55 |
| Valsartan 320 mg QD | Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -6.26 mmHg | Standard Error 0.544 |
| Olmesartan 40 mg QD | Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -7.82 mmHg | Standard Error 0.522 |
| Placebo QD | Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | 0.10 mmHg | Standard Error 0.718 |
p-value: <0.00195% CI: [-10.42, -6.87]ANCOVA
p-value: <0.00195% CI: [-9.52, -5.99]ANCOVA
p-value: 0.34195% CI: [-2.21, 0.77]ANCOVA
p-value: 0.00395% CI: [-3.8, -0.76]ANCOVA
p-value: 0.82195% CI: [-1.3, 1.64]ANCOVA
p-value: 0.07195% CI: [-2.89, 0.12]ANCOVA
Secondary
Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 6.
Population: Full Analysis Set.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Azilsartan Medoxomil 40 mg QD | Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -12.28 mmHg | Standard Error 0.778 |
| Azilsartan Medoxomil 80 mg QD | Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -13.32 mmHg | Standard Error 0.792 |
| Valsartan 320 mg QD | Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -9.66 mmHg | Standard Error 0.784 |
| Olmesartan 40 mg QD | Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -11.90 mmHg | Standard Error 0.752 |
| Placebo QD | Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -0.31 mmHg | Standard Error 1.035 |
p-value: <0.00195% CI: [-15.56, -10.45]ANCOVA
p-value: <0.00195% CI: [-14.51, -9.43]ANCOVA
p-value: 0.19495% CI: [-3.56, 0.72]ANCOVA
p-value: 0.00195% CI: [-5.84, -1.46]ANCOVA
p-value: 0.7295% CI: [-2.51, 1.73]ANCOVA
p-value: 0.01895% CI: [-4.79, -0.45]ANCOVA
Secondary
Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 6.
Population: Full Analysis Set.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Azilsartan Medoxomil 40 mg QD | Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -8.69 mmHg | Standard Error 0.648 |
| Azilsartan Medoxomil 80 mg QD | Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -8.61 mmHg | Standard Error 0.657 |
| Valsartan 320 mg QD | Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -6.22 mmHg | Standard Error 0.651 |
| Olmesartan 40 mg QD | Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -8.25 mmHg | Standard Error 0.624 |
| Placebo QD | Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -0.69 mmHg | Standard Error 0.859 |
p-value: 0.0195% CI: [-4.2, -0.57]ANCOVA
p-value: <0.00195% CI: [-10.03, -5.79]ANCOVA
p-value: <0.00195% CI: [-10.1, -5.88]ANCOVA
p-value: 0.69195% CI: [-2.14, 1.42]ANCOVA
p-value: 0.62595% CI: [-2.2, 1.32]ANCOVA
p-value: 0.00895% CI: [-4.27, -0.66]ANCOVA
Secondary
Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 6.
Population: Full Analysis Set.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Azilsartan Medoxomil 40 mg QD | Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -12.46 mmHg | Standard Error 0.86 |
| Azilsartan Medoxomil 80 mg QD | Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -13.38 mmHg | Standard Error 0.873 |
| Valsartan 320 mg QD | Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -9.14 mmHg | Standard Error 0.865 |
| Olmesartan 40 mg QD | Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -11.65 mmHg | Standard Error 0.829 |
| Placebo QD | Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -0.55 mmHg | Standard Error 1.142 |
p-value: <0.00195% CI: [-15.66, -10.02]ANCOVA
p-value: <0.00195% CI: [-14.72, -9.11]ANCOVA
p-value: 0.14995% CI: [-4.1, 0.62]ANCOVA
p-value: <0.00195% CI: [-6.65, -1.83]ANCOVA
p-value: 0.49495% CI: [-3.16, 1.53]ANCOVA
p-value: 0.00795% CI: [-5.72, -0.93]ANCOVA
Secondary
Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg
Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.
Time frame: Baseline and Week 6.
Population: Full analysis set with last observation carried forward.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Azilsartan Medoxomil 40 mg QD | Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg | 68.8 percentage of participants |
| Azilsartan Medoxomil 80 mg QD | Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg | 71.1 percentage of participants |
| Valsartan 320 mg QD | Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg | 63.8 percentage of participants |
| Olmesartan 40 mg QD | Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg | 68.2 percentage of participants |
| Placebo QD | Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg | 43.9 percentage of participants |
p-value: <0.00195% CI: [2.1, 5.15]Regression, Logistic
p-value: <0.00195% CI: [1.86, 4.54]Regression, Logistic
p-value: 0.30695% CI: [0.83, 1.8]Regression, Logistic
p-value: 0.13295% CI: [0.92, 1.97]Regression, Logistic
p-value: 0.69595% CI: [0.74, 1.58]Regression, Logistic
p-value: 0.38195% CI: [0.81, 1.74]Regression, Logistic
Secondary
Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg
Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.
Time frame: Baseline and Week 6.
Population: Full analysis set with last observation carried forward.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Azilsartan Medoxomil 40 mg QD | Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg | 56.5 percentage of participants |
| Azilsartan Medoxomil 80 mg QD | Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg | 57.8 percentage of participants |
| Valsartan 320 mg QD | Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg | 48.7 percentage of participants |
| Olmesartan 40 mg QD | Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg | 48.8 percentage of participants |
| Placebo QD | Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg | 22.3 percentage of participants |
p-value: <0.00195% CI: [3.15, 7.88]Regression, Logistic
p-value: <0.00195% CI: [2.94, 7.37]Regression, Logistic
p-value: 0.03295% CI: [1.03, 2.03]Regression, Logistic
p-value: 0.02995% CI: [1.04, 2.06]Regression, Logistic
p-value: 0.0895% CI: [0.96, 1.89]Regression, Logistic
p-value: 0.07195% CI: [0.97, 1.92]Regression, Logistic
Secondary
Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response
Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.
Time frame: Baseline and Week 6.
Population: Full analysis set with last observation carried forward.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Azilsartan Medoxomil 40 mg QD | Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response | 49.1 percentage of participants |
| Azilsartan Medoxomil 80 mg QD | Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response | 52.6 percentage of participants |
| Valsartan 320 mg QD | Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response | 43.9 percentage of participants |
| Olmesartan 40 mg QD | Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response | 44.5 percentage of participants |
| Placebo QD | Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response | 18.2 percentage of participants |
p-value: <0.00195% CI: [3.2, 8.41]Regression, Logistic
p-value: <0.00195% CI: [2.73, 7.19]Regression, Logistic
p-value: 0.05695% CI: [0.99, 1.94]Regression, Logistic
p-value: 0.03695% CI: [1.02, 2.02]Regression, Logistic
p-value: 0.31795% CI: [0.85, 1.66]Regression, Logistic
p-value: 0.23495% CI: [0.87, 1.73]Regression, Logistic